Today: 9 June 2026
Oil prices rise on Iran, Venezuela worries; Exxon and Chevron stocks jump premarket
9 January 2026
2 mins read

Oil prices rise on Iran, Venezuela worries; Exxon and Chevron stocks jump premarket

New York, Jan 9, 2026, 06:38 EST — Premarket

  • Exxon Mobil rose 3.7% and Chevron gained 2.6% in U.S. premarket trading, tracking firmer crude prices.
  • The White House is due to meet oil majors, traders and drillers on Venezuela later on Friday, keeping supply headlines in focus.
  • Traders are weighing supply disruption risks in Iran and uncertainty over Venezuelan exports, even as inventories have been rising and the market talks of oversupply.

Exxon Mobil was up $4.42, or 3.7%, in premarket trading on Friday, while Chevron added $4.08, or 2.6%, as oil-linked names caught a bid. ConocoPhillips rose 5.1%, while oilfield services firms Halliburton and SLB were also higher.

Moves in the group have turned on Venezuela again, with Washington pulling executives into a White House meeting that could shape who gets to market Venezuelan crude and where barrels end up. The guest list includes producers, refiners, traders and services firms, according to a White House official.

That matters because crude prices have been swinging between geopolitics and the drumbeat of ample supply, and any shift in sanctioned Venezuelan flows can hit U.S. Gulf Coast balances quickly. ConocoPhillips said its CEO would attend and it was watching Venezuela for “potential implications for global energy supply and stability.” reuters.com

In oil markets, Brent futures were up 43 cents, or 0.7%, at $62.42 a barrel, and U.S. West Texas Intermediate crude gained 41 cents, or 0.7%, to $58.17. “Iran protests seem to be gathering momentum, leading the market to worry about disruptions,” said Ole Hansen, head of commodity analysis at Saxo Bank. reuters.com

The Venezuela story is messy too. “The market will focus on the outcome in the coming days for how the Venezuelan oil in storage will be sold and delivered,” Tina Teng, market strategist at Moomoo ANZ, said. reuters.com

Investors are not treating a Venezuela return as a straight win for U.S. majors, even if the White House pitches it that way. “Investors will want to see long-lasting stability and good fiscal terms to protect against the risk of asset nationalization,” said David Byrns, a portfolio manager at American Century Investments, a major shareholder in both Chevron and Exxon. reuters.com

Company fundamentals are still tied to the last quarter’s softer crude. A regulatory filing showed Exxon said lower oil prices could cut fourth-quarter upstream earnings — the segment that produces oil and gas — by about $800 million to $1.2 billion, though stronger refining margins could partly offset that hit.

A big risk is that supply simply overwhelms the headlines. Morgan Stanley estimated the oil market could run a surplus of as much as 3 million barrels per day in the first half of 2026, and traders this week have pointed to expectations for ample global supply; U.S. crude inventories fell last week but fuel stockpiles rose, official data showed.

Next up: the White House meeting outcome later on Friday, followed by the next U.S. weekly inventory report on Jan. 14. Investors also have Jan. 30 circled for Exxon’s earnings call and Chevron’s quarterly earnings conference call.

Stock Market Today

  • Designer Brands (DBI) Beats Q1 Earnings and Revenue Estimates
    June 9, 2026, 10:04 AM EDT. Designer Brands (DBI) reported Q1 earnings of $0.07 per share, surpassing the Zacks estimate of $0.02 and reversing a year-ago loss of $0.26. Revenue hit $696.35 million, just above the $696 million consensus. The company delivered a 250% earnings surprise and has beaten EPS estimates in four consecutive quarters. Shares rose about 19.5% year-to-date, outpacing the S&P 500's 8.2% gain. Despite strong results, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. The Retail - Apparel and Shoes sector ranks among the top three industries. Future stock performance will depend on management's outlook and upcoming earnings estimate revisions, with current consensus estimates at $0.30 EPS on $744 million revenue next quarter and $0.35 EPS on $2.91 billion revenue for the fiscal year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Glencore stock jumps 8% on Rio Tinto merger talks as Feb 5 deadline looms
Previous Story

Glencore stock jumps 8% on Rio Tinto merger talks as Feb 5 deadline looms

Nano Nuclear Energy (NNE) stock jumps premarket as Meta nuclear deals put reactor names back in focus
Next Story

Nano Nuclear Energy (NNE) stock jumps premarket as Meta nuclear deals put reactor names back in focus

Go toTop